[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60117615D1 - Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen - Google Patents

Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen

Info

Publication number
DE60117615D1
DE60117615D1 DE60117615T DE60117615T DE60117615D1 DE 60117615 D1 DE60117615 D1 DE 60117615D1 DE 60117615 T DE60117615 T DE 60117615T DE 60117615 T DE60117615 T DE 60117615T DE 60117615 D1 DE60117615 D1 DE 60117615D1
Authority
DE
Germany
Prior art keywords
pentaamidine
chloropromazine
therapy
neoplastic diseases
medicinal combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60117615T
Other languages
English (en)
Other versions
DE60117615T2 (de
Inventor
Alexis Borisy
Curtis Keith
A Foley
R Stockwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zalicus Inc
Original Assignee
CombinatoRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CombinatoRx Inc filed Critical CombinatoRx Inc
Publication of DE60117615D1 publication Critical patent/DE60117615D1/de
Application granted granted Critical
Publication of DE60117615T2 publication Critical patent/DE60117615T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE60117615T 2000-11-06 2001-10-30 Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen Expired - Fee Related DE60117615T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/706,929 US6569853B1 (en) 2000-11-06 2000-11-06 Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US706929 2000-11-06
PCT/US2001/047959 WO2002058684A2 (en) 2000-11-06 2001-10-30 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders

Publications (2)

Publication Number Publication Date
DE60117615D1 true DE60117615D1 (de) 2006-04-27
DE60117615T2 DE60117615T2 (de) 2006-11-09

Family

ID=24839666

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60117615T Expired - Fee Related DE60117615T2 (de) 2000-11-06 2001-10-30 Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen

Country Status (29)

Country Link
US (4) US6569853B1 (de)
EP (1) EP1339399B1 (de)
JP (1) JP2004517915A (de)
KR (1) KR100720205B1 (de)
CN (1) CN1484525A (de)
AR (1) AR035500A1 (de)
AT (1) ATE318590T1 (de)
AU (1) AU2002246636B8 (de)
BG (1) BG107831A (de)
BR (1) BR0115166A (de)
CA (1) CA2436799C (de)
CY (1) CY1105501T1 (de)
DE (1) DE60117615T2 (de)
DK (1) DK1339399T3 (de)
EE (1) EE200300212A (de)
ES (1) ES2258566T3 (de)
HR (1) HRP20030460A2 (de)
HU (1) HUP0400529A3 (de)
IL (1) IL155795A0 (de)
IS (1) IS2457B (de)
MX (1) MXPA03003960A (de)
NO (1) NO20032036L (de)
NZ (1) NZ525773A (de)
PL (1) PL362690A1 (de)
PT (1) PT1339399E (de)
RU (1) RU2286769C2 (de)
SK (1) SK5452003A3 (de)
TW (1) TWI259077B (de)
WO (1) WO2002058684A2 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1231910E (pt) * 1999-11-16 2009-08-06 Oncozyme Pharma Inc Pentamidina para tratar o cancro
DE10015818A1 (de) * 2000-03-30 2001-10-18 Infineon Technologies Ag Biosensor und Verfahren zum Ermitteln makromolekularer Biopolymere mit einem Biosensor
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US6992082B2 (en) * 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
CA2451845A1 (en) * 2001-05-31 2002-12-05 The Cleveland Clinic Foundation Ptpase inhibitors and method of using same
FR2825279B1 (fr) * 2001-06-01 2005-04-08 Molecular Engines Lab Medicament utile dans le traitement du cancer
AU2002339904A1 (en) * 2001-09-07 2003-09-09 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
US20040010045A1 (en) * 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US20050215629A1 (en) * 2001-09-07 2005-09-29 Taolin Yi PTPase inhibitors and methods of using the same
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
AU2004201240B2 (en) * 2001-09-27 2008-08-07 Bar Ilan University Conjugated Psychotropic Drugs and Uses Thereof
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
AU2003241346A1 (en) * 2002-05-01 2003-11-17 The Cleveland Clinic Foundation Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
EP1545544A2 (de) * 2002-07-11 2005-06-29 Combinatorx, Incorporated Kombinationen von medikamenten für die behandlung von neoplasien
US7264933B2 (en) * 2003-03-26 2007-09-04 Synergy Biosystems Ltd Methods to identify biologically active agents and synergistic combinations
EP1651207A4 (de) * 2003-06-12 2008-10-01 Univ Colorado Systeme und verfahren zur behandlung von entzündlichen und proliferativen erkrankungen und wunden des menschen mit fettsäure-stoffwechsel-hemmern und/oder glykolytischen hemmern
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
WO2005020913A2 (en) * 2003-08-25 2005-03-10 Combinatorx, Incorporated Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
JP2007505914A (ja) * 2003-09-18 2007-03-15 コンビナトアールエックス インコーポレーティッド 新生物の治療のための薬物の併用方法
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
TW200526777A (en) * 2003-11-12 2005-08-16 Combinatorx Inc Combinations for the treatment of proliferative diseases
US8623864B2 (en) 2003-11-13 2014-01-07 Noa Sic Aps Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
EP2574341B1 (de) 2004-03-29 2017-03-29 University Of South Florida Wirksame Behandlung von Tumoren und Krebs mit Triciribin-Phosphat
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
CN1976723B (zh) 2004-04-30 2010-12-29 Bkg制药有限公司 制备治疗或预防感染性疾病的药物的用途
WO2005117847A2 (en) * 2004-06-02 2005-12-15 Combinatorx, Incorporated Methods and compounds for the treatment of neoplasms
CA2595156A1 (en) * 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Regulation of autophagy and cell survival
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
EP1877060A2 (de) * 2005-04-28 2008-01-16 The Regents of the University of Colorado Systeme und verfahren zur behandlung menschlicher entzündungskrankheiten und proliferativer erkrankungen mit einer für die hemmung des fettsäurestoffwechsels und der glykolyse sorgenden verbindung
US8329753B2 (en) * 2005-05-02 2012-12-11 The Regents Of The University Of Colorado Combination of compounds, or a bifunctional compound, that provides fatty acid metabolism and glycolysis inhibition
EP1896007B1 (de) 2005-05-04 2014-03-19 Medigene AG Verfahren zur verabreichung einer katonischen zubereitung aus liposomen, welche paclitaxel enthält
DE102005024017A1 (de) * 2005-05-25 2006-11-30 Merck Patent Gmbh Chinazolinone
US20090298814A1 (en) * 2005-06-07 2009-12-03 Ramot At Tel Aviv Univeristy Ltd Novel salts of conjugated psychotropic drugs and processes of preparing same
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
WO2007082052A2 (en) * 2006-01-11 2007-07-19 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
EP3056196A1 (de) 2006-03-22 2016-08-17 SynCore Biotechnology CO., LTD Behandlung von dreifach rezeptor-negativem brustkrebs
WO2007149381A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer
US20080226596A1 (en) * 2006-06-19 2008-09-18 Taolin Yi Therapeutic compositions and methods useful in treating hepatitis
WO2008010222A2 (en) * 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders
WO2008080398A1 (en) * 2007-01-05 2008-07-10 Bkg Pharma Aps Anti - infective agents such as phenothiazine and thioxanthene derivates to treat infectious diseases
US9308125B2 (en) * 2007-01-09 2016-04-12 Fovea Pharmaceuticals Apparatus for intra-ocular injection
DE102007013854A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Tetrahydrochinoline
DE102007013855A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
DE102007013856A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydropyrrolochinoline
WO2008138123A1 (en) * 2007-05-09 2008-11-20 Thomas David Y Screening assay to identify correctors of protein trafficking defects
CN101138558B (zh) * 2007-09-13 2010-08-25 汕头大学医学院 喷他脒及死亡结构域受体配体联合应用
EP2194981B1 (de) * 2007-10-05 2011-11-23 Université de Mons-Hainaut Bisbenzimidazole und mittel gegen malaria
US8207369B2 (en) * 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
WO2009148623A2 (en) * 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
WO2010009332A1 (en) * 2008-07-18 2010-01-21 Immune Control, Inc. Binding and inhibiting 5-ht4 receptor
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
CN102573826A (zh) * 2009-05-01 2012-07-11 奥克兹美制药公司 用于治疗癌症的喷他脒组合
EP2433133A2 (de) 2009-05-20 2012-03-28 Universite De Geneve Mitochondrienaktivitätsinhibitoren krebsauslösender zellen und verwendung davon
US20120277193A1 (en) * 2009-09-21 2012-11-01 President And Fellows Of Harvard College Synergistic Combination Therapy
MX2012006566A (es) * 2009-12-09 2012-11-29 Univ Ramot Metodo para mejorar las funciones cognoscitivas.
WO2011133966A2 (en) * 2010-04-23 2011-10-27 University Of Florida Research Foundation,Inc. Method and compositions for treating ace2-related disorders
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
HUE030245T2 (en) * 2011-07-25 2017-04-28 Dritte Patentportfolio Beteili Pentamidine amidoxime acid esters as prodrugs and their use as medicaments
US9504692B2 (en) 2011-08-02 2016-11-29 Helmholtz Zentrum Munchen, Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Selective inhibition of MALT1 protease by phenothiazine derivatives
WO2014086478A1 (en) * 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
US9375411B2 (en) 2012-12-21 2016-06-28 Verlyx Pharma Inc. Uses and methods for the treatment of liver diseases or conditions
RU2530651C1 (ru) * 2013-11-06 2014-10-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, обладающее противовоспалительным и антифибротическим действием в легочной ткани при цитостатическом воздействии
KR101538264B1 (ko) * 2014-01-24 2015-07-20 계명대학교 산학협력단 티오리다진과 트레일을 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물
CN105125571B (zh) * 2015-07-17 2018-11-06 四川大学 Prmt1抑制剂在制备治疗可卡因成瘾的药物中的用途
WO2020082037A1 (en) * 2018-10-19 2020-04-23 Auransa Inc. Methods for treating a subtype of small cell lung cancer
CN109793727A (zh) * 2019-03-13 2019-05-24 湖北科技学院 一种有效抗恶性肿瘤的药物组合物及其应用
KR102562739B1 (ko) * 2020-09-11 2023-08-03 연세대학교 산학협력단 암의 기원 세포의 사멸용 약학적 조성물
KR102315103B1 (ko) * 2021-01-21 2021-10-20 주식회사 뉴캔서큐어바이오 티오리다진 및 퍼헥실린을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) 1953-07-14 Phenthiazine derivatives
GB1288376A (de) 1968-10-29 1972-09-06
DE3827974A1 (de) 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US5104858A (en) 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
CH681780A5 (en) * 1991-02-25 1993-05-28 Patrinove Anticancer compsns. - consists of a cytotoxic agent with a agent to prevent multi:drug resistance, e.g. in liposome(s)
US5428051A (en) 1992-10-13 1995-06-27 University Of North Carolina Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
US5443962A (en) 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
US5521189A (en) 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
US5602172A (en) 1994-05-06 1997-02-11 The University Of North Carolina At Chapel Hill Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor
US5770585A (en) 1995-05-08 1998-06-23 Kaufman; Robert J. Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5723495A (en) 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
AU3511197A (en) 1996-07-03 1998-01-21 Prm Pharmaceuticals, Inc. Berberine alkaloids as a treatment for chronic, protozoally-induced diarrhea
US6008247A (en) 1998-02-27 1999-12-28 The University Of North Carolina At Chapel Hill 2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents
HUP0102612A2 (hu) 1998-03-12 2001-11-28 Novo Nordisk A/S Fehérje-tirozinfoszfatázokat moduláló vegyületek és ezeket tartalmazó gyógyászati készítmények
ATE239003T1 (de) 1998-08-20 2003-05-15 Univ North Carolina Dibenzothiophene derivate und ihre verwendung
JP2002524503A (ja) 1998-09-17 2002-08-06 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二陽イオン分子の抗真菌活性
JP3679943B2 (ja) * 1999-03-02 2005-08-03 大日本印刷株式会社 パターン形成体の製造方法
PT1231910E (pt) 1999-11-16 2009-08-06 Oncozyme Pharma Inc Pentamidina para tratar o cancro
US6777433B2 (en) 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
US6911468B2 (en) 2000-05-22 2005-06-28 Takeda Chemical Industries, Ltd. Tyrosine phosphatase inhibitors
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6642221B1 (en) 2000-11-15 2003-11-04 Parker Hughes Institute Vanadium compounds as anti-proliferative agents
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20030161893A1 (en) 2001-09-07 2003-08-28 Taolin Yi PTPase inhibitors and methods of using the same
EP1545544A2 (de) 2002-07-11 2005-06-29 Combinatorx, Incorporated Kombinationen von medikamenten für die behandlung von neoplasien
US20050054708A1 (en) 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
WO2005020913A2 (en) 2003-08-25 2005-03-10 Combinatorx, Incorporated Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
JP2007505914A (ja) 2003-09-18 2007-03-15 コンビナトアールエックス インコーポレーティッド 新生物の治療のための薬物の併用方法
US20050158320A1 (en) 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US20050100508A1 (en) 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases

Also Published As

Publication number Publication date
US20030166642A1 (en) 2003-09-04
IL155795A0 (en) 2003-12-23
HUP0400529A3 (en) 2006-02-28
WO2002058684A3 (en) 2003-04-17
CY1105501T1 (el) 2010-04-28
EE200300212A (et) 2003-08-15
AU2002246636B8 (en) 2006-01-19
AR035500A1 (es) 2004-06-02
US6569853B1 (en) 2003-05-27
ATE318590T1 (de) 2006-03-15
IS6806A (is) 2003-05-05
NO20032036D0 (no) 2003-05-06
US7148216B2 (en) 2006-12-12
DK1339399T3 (da) 2006-06-19
NO20032036L (no) 2003-07-04
HRP20030460A2 (en) 2005-04-30
NZ525773A (en) 2005-04-29
US20070099906A1 (en) 2007-05-03
BG107831A (bg) 2004-02-27
EP1339399A2 (de) 2003-09-03
CA2436799A1 (en) 2002-08-01
PT1339399E (pt) 2006-07-31
HUP0400529A2 (hu) 2004-06-28
EP1339399B1 (de) 2006-03-01
TWI259077B (en) 2006-08-01
ES2258566T3 (es) 2006-09-01
KR100720205B1 (ko) 2007-05-21
JP2004517915A (ja) 2004-06-17
AU2002246636B2 (en) 2005-12-01
SK5452003A3 (en) 2004-07-07
MXPA03003960A (es) 2004-09-10
CN1484525A (zh) 2004-03-24
IS2457B (is) 2008-11-15
RU2286769C2 (ru) 2006-11-10
PL362690A1 (en) 2004-11-02
WO2002058684A2 (en) 2002-08-01
KR20030048460A (ko) 2003-06-19
US6846816B2 (en) 2005-01-25
BR0115166A (pt) 2003-12-30
US20050192274A1 (en) 2005-09-01
DE60117615T2 (de) 2006-11-09
CA2436799C (en) 2007-12-18

Similar Documents

Publication Publication Date Title
DE60117615D1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69807634D1 (de) Medizinische einrichtung zur verabreichung von therapeutischen wirkstoffen
IS5500A (is) Lyfjablöndur til öftrunar og meðferðar mýlildi ogtengdum sjúkdómum
DE60126321D1 (de) Gelsystem zur ocularen verabreichung von arzneimitteln
NO20041277L (no) Farmasoytiske preparater for behandling av astma.
DE69927388D1 (de) Gerät zur verabreichung von medikamenten und genen in gewebe
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60115418D1 (de) Mikroinfusionsvorrichtung zur verabreichung von medikamenten
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
AR028426A1 (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero
DE69917477D1 (de) Vorrichtung zur arzneistoffabgabe, insbesondere zur verabreichung von progestinen und östrogenen
DE19580261D2 (de) Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktion
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
NO983465L (no) Farmasöytisk kombinasjonspreparater inneholdende LHRH-analoger og antiöstrogener for behandling av gynekologiske forstyrrelser
NO20023448L (no) Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
GB0019302D0 (en) Biological materials and the use thereof for the treatment of disease
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
HK1064042A1 (en) Medicines and medicinal kits
DE69519602D1 (de) Kugelförmige Aktivkohle zur Behandlung von Hämorrhoiden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee